Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - nevirapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; povidone - nevirapine viatris in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults. resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - nevirapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; colloidal anhydrous silica; sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose - nevirapine in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nevirapine, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; lactose; microcrystalline cellulose; crospovidone; copovidone - nevirapine immediate-release tablets in combination with antiretroviral agents are indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nevirapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - nevirapine scp immediate-release tablets in combination with antiretroviral agents are indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years. resistant virus emerges rapidly when nevirapine scp is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine scp should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nevirapine, quantity: 400 mg - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; iron oxide yellow; magnesium stearate - viramune (nevirapine) oral suspension in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of 2 months. viramune xr (nevirapine) extended-release tablets in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of three years. extended-release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. resistant virus emerges rapidly when viramune is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, viramune should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nevirapine, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; crospovidone; copovidone - nevirapine immediate-release tablets in combination with antiretroviral agents are indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nevirapine, quantity: 200 mg - tablet - excipient ingredients: lactose; copovidone; microcrystalline cellulose; magnesium stearate; crospovidone - nevirapine immediate-release tablets in combination with antiretroviral agents are indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - nevirapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; sodium starch glycollate type a - nevirapine in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - nevirapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; magnesium stearate; povidone; sodium starch glycollate type a - nevirapine in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and adolescents over the age of 16 years.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nevirapine hemihydrate, quantity: 10.35 mg/ml (equivalent: nevirapine, qty 10 mg/ml) - oral liquid, suspension - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); propyl hydroxybenzoate; sodium hydroxide; carbomer 934p; polysorbate 80; sucrose; methyl hydroxybenzoate - viramune (nevirapine) oral suspension in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of 2 months. viramune xr (nevirapine) extended-release tablets in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of three years. extended-release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. resistant virus emerges rapidly when viramune is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, viramune should always be administered in combination with at least two additional antiretroviral agents.